new version V2017

direct oral anticoagulant (DAO)
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009apixabanplacebo Exploratory Negative NCT00313300
APPRAISE-1 (2.5 mg bid), 2009apixabanplaceboNegativeNCT00313300
APPRAISE 2, 2011apixabanplacebo Low risk of bias Negative NCT00831441
APPRAISE japan ongoing apixabanplacebo Exploratory - NCT00852397
dabigatran
REDEEM, 2009dabigatranplaceboNegativeNCT00621855
otamixaban
SEPIA-ACS1 TIMI 42, 2009otamixabanunfractionated heparin Exploratory SuggestingNCT00317395
rivaroxaban
ATLAS ACS-TIMI 46 (2.5mg), 2009rivaroxaban 2.5mgplaceboNegativeNCT00402597
ATLAS ACS-TIMI 46 (5mg), 2009rivaroxaban 5mgplaceboNegative NCT00402597
ATLAS ACS 2 - TIMI 51 (5mg), 2011rivaroxaban 5mgplaceboSuggesting NCT00809965
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011rivaroxaban 2.5mgplacebo Low risk of bias Suggesting NCT00809965
ximelagatran
ESTEEM, 2003ximelagatranplacebo Exploratory -

atrial fibrillation

apixaban
phase 2 apixabanapixabanwarfarin standard dose Exploratory - NCT00787150
ARISTOTLE, 2011apixabanwarfarin standard dose Low risk of bias ConclusiveNCT00412984
dabigatran
phase 2 dabigatrandabigatranwarfarin standard dose Exploratory - NCT01136408
PETRO (150mg), 2007dabigatran 150mgwarfarin standard dose Exploratory -
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard dose Risk of bias SuggestingNCT00262600
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard dose Risk of bias Suggesting NCT00262600
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard dose Exploratory - NCT00504556
phase 2 edoxabanedoxabanwarfarin standard dose Exploratory - NCT00806624
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard dose Low risk of bias Suggesting NCT00781391
idraparinux
AMADEUS, 2008idraparinuxwarfarin standard dose Risk of bias Negative NCT00070655
idraparinux BOREALIS-AF ongoing idraparinuxwarfarin standard dose - NCT00580216
rivaroxaban
ROCKET-AF, 2010rivaroxabanwarfarin standard dose Low risk of bias Suggesting NCT00403767
ROCKET J ongoing rivaroxabanwarfarin standard dose - NCT00494871
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard dose Risk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard dose Risk of bias Suggesting
SPORTIF V, 2005ximelagatranwarfarin standard dose Low risk of bias Suggesting

cardiovascular prevention

rivaroxaban
COMPASS (rivaroxaban alone), 2017rivaroxabanaspirinsecondary prevention - NCT01776424
COMPASS (rivaroxaban + aspirin), 2017rivaroxaban + aspirinaspirinsecondary prevention Low risk of bias - NCT01776424

heart failure

rivaroxaban
COMMANDER HF, 2018rivaroxabanplaceboNegativeNCT01877915

thrombosis prevention

apixaban
APROPOS 2.5mg, 2007apixabanenoxaparin (US regimen)knee surgery Exploratory NegativeNCT00097357
ADVANCE-1, 2008apixabanenoxaparin (US regimen)knee surgery Low risk of bias SuggestingNCT00371683
ADVANCE 3, 2010apixabanenoxaparinhip surgery Low risk of bias SuggestingNCT00423319
ADVANCE 2, 2010apixabanenoxaparin (europe regimen)knee surgery Low risk of bias SuggestingNCT00452530
ADOPT, 2011apixabanenoxaparinmedical patients Low risk of bias SuggestingNCT00457002
betrixaban
APEX, 2016betrixabanenoxaparinmedical patients Low risk of bias SuggestingNCT01583218
dabigatran
RE-NOVATE 2dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00657150
RE-NOVATE (220mg), 2007dabigatran 220mgenoxaparinhip surgery Low risk of bias NegativeNCT00168818
RE-NOVATE (150mg), 2007dabigatran 150mgenoxaparinhip surgery Low risk of bias Negative NCT00168818
RE-MODEL (220mg), 2007dabigatran 220mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MODEL (150mg), 2007dabigatran 150mgenoxaparin (europe regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (220mg), 2008dabigatran 220mgenoxaparin (US regimen)knee surgery Low risk of bias Negative
RE-MOBILIZE (150mg), 2008dabigatran 150mgenoxaparin (US regimen)knee surgery Low risk of bias Negative
edoxaban
STARS J-Vedoxabanenoxaparin (short duration)hip surgery Low risk of bias SuggestingNCT01181167
DU176b-B-J304 ongoing edoxabanenoxaparinhip surgery - NCT01181167
DU176b-B-J303 ongoing edoxabanenoxaparinhip surgery - NCT01181141
DU176b-B-J302 ongoing edoxabanenoxaparinknee surgery - NCT01181102
DU176b-04 ongoing edoxabanplaceboknee surgery - NCT01203072
rivaroxaban
ODIXa-KNEE, 2005rivaroxabanenoxaparin (US regimen)knee surgery Exploratory Negative
ODIXa-HIP 10mg, 2006rivaroxabanenoxaparin (short duration)hip surgery Exploratory Suggesting
RECORD 1, 2008rivaroxabanenoxaparinhip surgery Low risk of bias SuggestingNCT00329628
RECORD 3, 2008rivaroxabanenoxaparin (europe regimen)knee surgery Low risk of bias SuggestingNCT00361894
RECORD 2, 2008rivaroxaban (long duration)enoxaparin (short duration)hip surgery Low risk of bias SuggestingNCT00332020
RECORD 4, 2009rivaroxabanenoxaparin (US regimen)knee surgery Low risk of bias SuggestingNCT00362232
MARINER, 2018rivaroxabanplacebomedical patientsSuggesting NCT02111564

venous thrombosis

apixaban
Botticelli DVT, 2008apixaban (without LMWH)LMWH/VKA Exploratory - NCT00252005
AMPLIFY-EXT 2.5mg, 2012apixaban 2.5mgdiscontinuationSuggestingNCT00633893
AMPLIFY-EXT 5mg, 2012apixaban 5mgdiscontinuationSuggestingNCT00633893
AMPLIFY, 2013apixaban (without LMWH)LMWH/VKA Low risk of bias SuggestingNCT00643201
CAP ongoing apixaban - NCT02581176
CARAVAGGIO ongoing apixabandalteparin - NCT03045406
dabigatran
RE-COVER, 2009heparin/dabigatranheparin/VKA Low risk of bias SuggestingNCT00291330
RE-SONATE, 2011dabigatrandiscontinuationSuggestingNCT00558259
RE-COVER II, 2011heparin/dabigatranheparin/VKASuggestingNCT00680186
RE-MEDY, 2011dabigatranwarfarin Low risk of bias SuggestingNCT00329238
edoxaban
Edoxaban Hokusai VTE, 2013heparin/edoxabanheparin/VKA Low risk of bias SuggestingNCT00986154
Hokusai-VTE Cancer, 2017edoxabandalteparinpatients with cancerNegative NCT02073682
idraparinux
Van Gogh (subgroup), 2011idraparinuxstandard treatmentpatients with cancer Exploratory Negative
rivaroxaban
Einstein-DVT Dose-Ranging Study, 2008rivaroxaban (without LMWH)LMWH/VKA -
EINSTEIN-extension, 2009rivaroxabandiscontinuation Low risk of bias Suggesting NCT00439725
Einstein-DVT Evaluation, 2010rivaroxaban (without LMWH)LMWH/VKA Low risk of bias SuggestingNCT00440193
Einstein-PE Evaluation, 2012rivaroxaban (without LMWH)LMWH/VKA Risk of bias - NCT00439777
EINSTEIN (subgroup), 2014rivaroxabanenoxaparinpatients with cancerSuggesting
SELECT D, 2018rivaroxabandalteparinpatients with cancerSuggesting
CONKO-011 ongoing rivaroxaban - NCT02583191
CASTA-DIVA ongoing rivaroxaban - NCT02746185
rosuvastatin
VanGogh extension, 2007idraparinuxdiscontinuationSuggesting NCT00071279
ximelagatran
THRIVE III, 2003ximelagatrandiscontinuation Low risk of bias Suggesting
THRIVE I, 2003ximelagatran (without LMWH)LMWH/VKA -
Schulman (subgroup), 2003ximelagatranplacebopatients with cancer -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons